浙江医学2017，Vol.39Issue(18)：1536-1543,1547,9.DOI:10.12056/j.issn.1006-2785.2017.39.18.2017-134
地诺单抗与唑来膦酸治疗恶性肿瘤伴骨转移安全性和有效性的Meta分析
Efficacy and safety of denosumab versus zoledronic acid in treatment of bone metastasis: a meta-analysis
陈皖京 1王蓓 1高秀飞 1徐小宏 1张颈 1胡袁媛1
作者信息
摘要
Abstract
Objective To evaluate the effectiveness and safety of denosumab versus zoledronic acid in treatment of bone metastasis in cancer patients.Methods Clinical studies of denosumab and zoledronic acid in treating bone metastasis were searched from Cochrane Library,PubMed,OVID,Springer Linker,Science Direct,EBSCO and other databases.The quality of literature were evaluated with Cochrane risk of bias assessment tools.The meta-analysis was performed with software Rev Man 5.3.Results Four RCTs reported in 7 papers and involving 6029 patients were included in the meta-analysis.Meta-analysis showed that denosumab was superior to zoledronic acid in delaying the time to skeleton-related events (SREs),decreasing the concentration of bone metastasis markers uNTx/Cr and S-BALP,prolonging the time to radiotherapy,reducing the pain severity and pain interference.The denosumab group had lower incidence rate of anemia,acute phase reactions and renal toxicity.There were no significant differences in overall survival,disease progression,pathologic fractures,surgery to bone,spinal cord compression and incidence rates of nausea,fatigue,back pain,osteonecrosis of the jaw between two groups.Conclusion Denosumab is superior to zoledronic acid in clinical efficacy and safety for treatment of bone metastasis in cancer patients.关键词
地诺单抗/唑来膦酸/骨相关事件/骨转移/恶性肿瘤Key words
Denosumab/Zoledronic acid/Skeletal-related events/Bone metastasis/Neoplasms引用本文复制引用
陈皖京,王蓓,高秀飞,徐小宏,张颈,胡袁媛..地诺单抗与唑来膦酸治疗恶性肿瘤伴骨转移安全性和有效性的Meta分析[J].浙江医学,2017,39(18):1536-1543,1547,9.
